MedTrace Logo

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

NCT05169671 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-04-08

No results posted yet for this study

Summary

This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of ATH-1020 in healthy young and elderly subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ATH-1020

ATH-1020 in oral capsule form

DRUG

Placebo

Placebo in oral capsule form

Sponsors & Collaborators

  • Biotrial Inc.

    collaborator UNKNOWN

  • Alturas Analytics, Inc.

    collaborator UNKNOWN

  • Athira Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-30
Primary Completion
2022-09-09
Completion
2022-09-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05169671 on ClinicalTrials.gov